Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

Xanderzzzzzzz Apr. 25 at 6:56 PM

$CADL $IOVA $CATX

3 · Reply

badprecog Apr. 25 at 2:24 PM

$CADL https://www.bioprocessonline.com/doc/mapping-candel-therapeutics-sprint-to-the-bla-finish-line-0001 worth a read!

2 · Reply

jacksparo Apr. 25 at 2:22 PM

$SLS I am collecting the volume analysis for this week , last night AH closed above 4.60 with some volume after hours. We will see what the affect by Monday I am working on some updates ( I will share in my live Telegram biotech group) $CADL Today shared my first plan with some details in my Live Biotech group. Time has come to share it as I have been collecting info in the last two weeks and a lot of details to create my plan ✅! I don’t trade randomly ✅! $IBRX A lot of short sellers are hitting this board lately the funny thing is checking their posts they first sounds like bulls then next day they start the bearish sentiments posts such an old lazy repeated style! Why they can’t improve?? Maybe 🤔 multi vitamins or watching tiktok plus youtube are not helping their IQ declining status. Regardless I will keep swing to long I care about making money ✅! And I will share some new plans about it when time comes! $OCGN A lot of nonsense talk is going around. Yes they proposed a reverse split not approved yet. The meeting in June. Their Earning on May 8th maybe 🤔 before the market opens. I think by then they will most likely say something. The volatility might be high and it could be not a smooth ride but over the years swing to long plus taking advantage of the binary events helped me understand this one nature. Enjoy the rest of your weekend! ( my full live biotech stocks updates I always share in my Live Biotech group , nothing shared to be seen as a financial advice everything I share for educational purposes only, please be careful trading any stock in this market without doing your DD and understanding the risk involved).

1 · Reply

drizz Apr. 25 at 11:01 AM

$CADL part 2

0 · Reply

drizz Apr. 25 at 11:01 AM

$CADL all should read this

1 · Reply

stockpicker63 Apr. 25 at 7:39 AM

Top traders this week delivering strong results in a volatile market 📈 $USAS +15.6% $MP +10.5% $CADL +8.5% $CTOS +7.5% Consistency, discipline, and the right system make the difference.

0 · Reply

J_machete Apr. 25 at 6:52 AM

$CADL we have to keep adding

0 · Reply

PatientHarvester Apr. 25 at 5:05 AM

$CADL We will be in a much better spot as the NSCLC Phase 3 progresses and the BLA submission approaches. By then, commercial preparations will also be near completion. I couldn't care less about Candel’s typical 'pendulum' price action. My plan is to invest in lockstep with Tak’s strategy. The data is solid, and the drug will undoubtedly be an appealing treatment for doctors.

0 · Reply

strategicmind Apr. 25 at 2:20 AM

$CADL my answer to this question is B! Option B has the higher expected return of 150% Expected return A= 50% B= (0.5 x 300%) + (0.5 x -50%) =150% Now let’s apply this to CADL. Cantors math below… Expected return for CADL (0.13 x 1300%) + (0.5 x 370%) + (0.37 x -50%) = 335.5% 😉

3 · Reply

strategicmind Apr. 25 at 2:14 AM

$CADL Pop Quiz for the board… which stock would you prefer? A) stock has 100% guarantee of a 50% rate of return over let’s say 2 years B) stock has 50% chance of 300% return or 50% chance of -50% return. What would you prefer?

3 · Reply

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Apr 2, 2026, 4:05 PM EDT - 23 days ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2026, 8:05 AM EDT - 5 weeks ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Mar 12, 2026, 8:05 AM EDT - 6 weeks ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 9, 2026, 8:05 AM EDT - 6 weeks ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 3, 2026, 11:50 AM EST - 7 weeks ago

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:05 AM EST - 2 months ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Feb 20, 2026, 4:57 AM EST - 2 months ago

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus

CPRT IVV SPXL SPY SSO UPRO VOO

Feb 19, 2026, 9:40 PM EST - 2 months ago

Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 4:05 PM EST - 2 months ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 2 months ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026, 8:05 AM EST - 2 months ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Dec 5, 2025, 11:00 AM EST - 5 months ago

Candel Therapeutics Transcript: R&D Day 2025

Nov 18, 2025, 3:00 AM EST - 5 months ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 4:05 PM EST - 5 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025, 8:25 AM EST - 5 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 6 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 6 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 6 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 6 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 3, 2025, 9:05 AM EDT - 7 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:00 AM EDT - 8 months ago

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 13, 2025, 2:00 PM EDT - 9 months ago

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 10 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 5, 2025, 11:40 AM EDT - 11 months ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 1 year ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 14, 2025, 7:20 PM EDT - 1 year ago

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 1 year ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 9:19 AM EST - 1 year ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 8:30 AM EST - 1 year ago

Candel Therapeutics Transcript: Study Result

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 20, 2024, 4:30 AM EST - 1 year ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Candel Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Jan 19, 2023, 11:30 AM EST - 3 years ago

Candel Therapeutics Transcript: B. Riley Securities' 3rd Annual Oncology Conference

Xanderzzzzzzz Apr. 25 at 6:56 PM

$CADL $IOVA $CATX

3 · Reply

badprecog Apr. 25 at 2:24 PM

$CADL https://www.bioprocessonline.com/doc/mapping-candel-therapeutics-sprint-to-the-bla-finish-line-0001 worth a read!

2 · Reply

jacksparo Apr. 25 at 2:22 PM

1 · Reply

drizz Apr. 25 at 11:01 AM

$CADL part 2

0 · Reply

drizz Apr. 25 at 11:01 AM

$CADL all should read this

1 · Reply

stockpicker63 Apr. 25 at 7:39 AM

Top traders this week delivering strong results in a volatile market 📈 $USAS +15.6% $MP +10.5% $CADL +8.5% $CTOS +7.5% Consistency, discipline, and the right system make the difference.

0 · Reply

J_machete Apr. 25 at 6:52 AM

$CADL we have to keep adding

0 · Reply

PatientHarvester Apr. 25 at 5:05 AM

0 · Reply

strategicmind Apr. 25 at 2:20 AM

3 · Reply

strategicmind Apr. 25 at 2:14 AM

3 · Reply

Dkll303 Apr. 25 at 1:02 AM

$SRPT way back , I owned this at $28….got out at $105..in 2017 ..I felt ahaead of itself then .doug came as ceo in july 2017, I was vacationing in France . He put 2M of his own money in at $44, and started his gig. Within 1 year of that July he vowed not to sell the company for less than $185. He had his chance . Since 2018 , lots of ups and downs , which I played with more successes , he now he wants out ( having never selling his Orange County home ) it was always a take out . How it plays out now, is anyone’s guess . All stated is true, for the losers sitting with TAK at $CADL and the misfits running a welfare office for themselves at $AGIO .read it and weep , you pathetic fools

2 · Reply

Dkll303 Apr. 24 at 11:47 PM

$CADL and @claybridge , blocked me , while all along for 2. Years I have been saying the same thing ..NOT GOING ANYWHERE. Buy it when, TAK’s HYPE goes to crickets, and the TAK minions who are basically broke , have to watch the Big Money Men take over !!!

0 · Reply

Dkll303 Apr. 24 at 11:44 PM

$CADL you mean penniless pumpers ???

1 · Reply

DrHierba Apr. 24 at 9:42 PM

$CADL Despite this, many healthcare providers and even patients feel uncomfortable not administering it to those at low risk, since both the patient and we feel reassured knowing that any remaining thyroid tissue, whether benign or malignant, has been wiped out with the radioiodine administered after surgery. As you may have noticed, CAN-2409 presents a similar profile: comparable efficacy and a very favorable side-effect profile— the necessary ingredients to become a revolutionary therapy and eventually establish itself as the standard of care. Additionally, we must not forget that there is an ongoing study exploring its potential efficacy in those patients selected for active surveillance. I also think it should be explored whether it could work in stage IV, given the documented abscopal effect in NSCLC.

1 · Reply

DrHierba Apr. 24 at 9:42 PM

$CADL I speak to you from the perspective of an endocrinologist, so take it with a grain of salt. The truth is that in endocrinology, we have a condition with a similar behavior to prostate cancer, which is thyroid cancer. Like prostate cancer, it is usually, in most cases, slow-growing and has a good prognosis. Similar to prostate cancer, there is a curative treatment like surgery and an adjuvant treatment like radioiodine. It turns out that aglatimagene besadenovec has efficacy translated into PFS that is quite similar to radioiodine in thyroid cancer (results from retrospective studies since it has been used for many years as an adjuvant treatment). Until 15 years ago, it was given to every patient with thyroid cancer, but in recent years, the guidelines have recommended administering it only to those at intermediate or high risk of recurrence.

0 · Reply

jacksparo Apr. 24 at 8:46 PM

$SLS $NRXP $OCGN $IBRX $CADL The market Regular hours closed. Time to review the whole week activity plus action: I will go through: The daily volume The weekly volume Any PR for this week Any filling ( prospects or institutions) The short interests The most important 16 to 23 technical indicators! All the possible catalysts and what might went wrong! As usual I am sharing and will share my live daily updates in my Live Biotech group! I will take it easy and relax as until this moment I am not concerned or need to be! Enjoy the rest of your evening ✅📈✅!

4 · Reply

Dkll303 Apr. 24 at 8:43 PM

$CADL Gee …gone a day and guess what NOTHING ….ya got NOTHING ..repeat of 2025

0 · Reply

Xanderzzzzzzz Apr. 24 at 8:33 PM

$CADL https://www.washingtonpost.com/world/2026/04/24/netanyahu-prostate-cancer-treatment-iran-war/

1 · Reply

badprecog Apr. 24 at 8:20 PM

$CADL So candel is using the new process for the p3 for lung, in the p2 they used the old batch. To make this change the FDA will have done the same tests on the drug and process to verify the manufacturing process as will take place for the drug approval process. So, once we have our first patient dosed in p3 in lung we are more or less out of the woods on manufacturing. You could still have a mess up by he contract manufacturing however sounds like they are the best in the business.

2 · Reply

Vermicelli_ Apr. 24 at 8:10 PM

$CADL Here is a shoutout to @claybridge who gently suggested waiting for a pullback to buy after the run-up on Monday. I asked what price we might wait for based on the tech analysis, and this was his response. Exactly where it landed at the end of the day today. Mad respect to Clay for his TA, and all here who provide their expertise, whether on the science, the financials, or technical analysis. Thank you all, let's celebrate a great week!

2 · Reply

YeboGogo Apr. 24 at 8:09 PM

$IBRX $CADL kudos to those dumping... and for your next miracle? Looking forward to a Great weekend as I anticipate the inevitable rip higher & epic short squeeze 🚀🚀🚀--- investing is easy when you are riding profits, weee. Can't shake these hands 💎

0 · Reply

TurdSniper Apr. 24 at 7:59 PM

$CADL Glad I shorted this turd today ⬇💩

1 · Reply

Market Cap	515.66M
Revenue (ttm)	0.00
Net Income (ttm)	-38.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.91

Volume	1,691,600
Avg Vol	1,598,056
Day's Range	N/A - N/A
Shares Out	73.25M
Stochastic %K	58%
Beta	-0.81
Analysts	Strong Sell
Price Target	$18.88